Aura Biosciences, Inc. (NASDAQ:AURA) Given Average Rating of “Buy” by Brokerages

Aura Biosciences, Inc. (NASDAQ:AURA) has been assigned a consensus recommendation of “Buy” from the seven brokerages that are currently covering the company, MarketBeat Ratings reports. Five investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $23.00.

Separately, Lifesci Capital upgraded Aura Biosciences to a “strong-buy” rating in a research note on Friday, January 31st.

Aura Biosciences Stock Performance

Shares of NASDAQ:AURA opened at $7.50 on Monday. Aura Biosciences has a twelve month low of $6.63 and a twelve month high of $12.38. The firm has a market cap of $374.63 million, a PE ratio of -4.34 and a beta of 0.30. The business has a fifty day moving average of $7.66 and a 200-day moving average of $8.65.

Insiders Place Their Bets

In other Aura Biosciences news, insider Los Pinos Elisabet De sold 15,955 shares of Aura Biosciences stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $7.67, for a total transaction of $122,374.85. Following the completion of the sale, the insider now owns 304,692 shares of the company’s stock, valued at approximately $2,336,987.64. The trade was a 4.98 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In the last 90 days, insiders sold 23,045 shares of company stock valued at $177,242. Company insiders own 5.40% of the company’s stock.

Hedge Funds Weigh In On Aura Biosciences

A number of hedge funds and other institutional investors have recently made changes to their positions in AURA. Charles Schwab Investment Management Inc. boosted its position in shares of Aura Biosciences by 2.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 138,356 shares of the company’s stock worth $1,233,000 after purchasing an additional 3,612 shares in the last quarter. State Street Corp boosted its position in shares of Aura Biosciences by 3.7% during the third quarter. State Street Corp now owns 754,803 shares of the company’s stock worth $6,725,000 after purchasing an additional 26,841 shares in the last quarter. Wellington Management Group LLP bought a new position in shares of Aura Biosciences during the third quarter worth $1,037,000. Barclays PLC boosted its position in shares of Aura Biosciences by 256.5% during the third quarter. Barclays PLC now owns 61,010 shares of the company’s stock worth $544,000 after purchasing an additional 43,897 shares in the last quarter. Finally, Geode Capital Management LLC boosted its position in shares of Aura Biosciences by 4.1% during the third quarter. Geode Capital Management LLC now owns 1,008,827 shares of the company’s stock worth $8,990,000 after purchasing an additional 39,379 shares in the last quarter. 96.75% of the stock is owned by institutional investors.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.